Cardiovascular Health
14 articles on Cardiovascular Health, written by Shotlee and medically reviewed for clinical accuracy.
Semaglutide and Blood Pressure Meds: Why Dizziness Risk Is Rising
A new study reveals a potential safety concern when combining GLP-1 medications with blood pressure drugs, highlighting the importance of monitoring hypotensive episodes in select patients.
8 min read
Ozempic, Wegovy & Mounjaro: Navigating Dizziness and Fainting Risks
Recent research highlights a potential safety concern with GLP-1 medications, linking them to an increased risk of dizziness and fainting, particularly in certain patient groups. Discover what this means for your health.
6 min read
Beyond Weight Loss: How GLP-1s Impact Your Blood Pressure
GLP-1 receptor agonists, known for their role in diabetes and weight management, are increasingly recognized for their broader health benefits, including effects on blood pressure. This article delves into how these medications work, their impact on cardiovascular health, and whether they are safe for individuals with hypertension.
8 min read
Beyond Glucose: GLP-1 Therapies Reshape Metabolic Care
The GLP-1 receptor agonist market is experiencing explosive growth, transforming from a diabetes-focused treatment to a cornerstone of comprehensive metabolic care. Discover the key drivers, leading molecules like semaglutide and tirzepatide, and the future outlook.
10 min read
Ozempic, Wegovy, Mounjaro: The GLP-1 Revolution Reshaping Health
The GLP-1 analogue market is experiencing unprecedented growth, transforming from diabetes treatments to comprehensive cardiometabolic solutions. Discover the key drivers, leading medications, and future innovations shaping this dynamic field.
9 min read
Semaglutide & Heart Health: New Insights on Atrial Fibrillation Prevention
Emerging research from Ben-Gurion University suggests Semaglutide and Colchicine may prevent atrial fibrillation by reducing inflammation and cardiac scarring.
8 min read
Genetic Variations Linked to GLP-1 Weight Loss, Side Effects
New research from 23andMe reveals genetic variants in GLP1R that boost weight loss from GLP-1 drugs by up to 3.3 pounds. GIPR mutations increase vomiting risk on tirzepatide. Meanwhile, semaglutide's heart benefits appear independent of weight loss, opening doors to precision dosing.
5 min read
FDA Approves Triple Max Dose of Wegovy: 7.2mg Now Available
The FDA just greenlit a groundbreaking higher dose of Wegovy, tripling the previous maximum to 7.2 milligrams for enhanced weight management. Patients saw up to 21% body weight loss, with unique cardiovascular protections. Here's what this means for obesity treatment and access.
5 min read
Healthy Lifestyle Enhances GLP-1 Therapy's CV Benefits in Type 2 Diabetes
New research reveals that pairing GLP-1 receptor agonists with healthy lifestyle habits significantly lowers heart attack, stroke, and CV death risk in type 2 diabetes patients. Those following 6-8 habits plus GLP-1 therapy saw a 43% reduced MACE risk. This study highlights their complementary roles in heart health.
5 min read
Cardiologist: GLP-1 Drugs Benefits Beyond Weight Loss for Heart, Liver
Cardiologist Dmitry Yaranov states GLP-1 drugs like Ozempic, Wegovy, and Mounjaro offer benefits far beyond weight loss. They enhance cardiovascular health, combat fatty liver disease, and improve blood sugar control in diabetes patients. These medications could redefine treatment for heart, liver, and metabolic diseases.
1 min read
newsGP - Wegovy Suggested for PBS Inclusion
Semaglutide (Wegovy) is nearing PBS inclusion for adults with cardiovascular disease and obesity, following a PBAC recommendation. The recommendation identifies specific groups to prioritize for access to GLP-1 receptor agonist medicines.
2 min read
Novo Nordisk's Oral Wegovy Lowers Cardiovascular Risk Factors in Obesity Patients
The Phase III OASIS 4 trial revealed that Novo Nordisk's oral Wegovy (semaglutide) reduced cardiovascular risk factors in individuals with obesity. The study supports the drug's approval, showing improvements in C-reactive protein and serum triglycerides. Blood sugar control also improved among patients.
3 min read
Wegovy's Breakthrough: How GLP-1 Therapies are Revolutionizing Weight Loss & Heart Health
New Wegovy trial results are making waves, showing impressive weight loss and cardiovascular benefits. Discover how GLP-1 therapies are transforming healthcare.
4 min read
FDA Approves New Treatments: Oral Semaglutide & Lupus Nephritis Drug
The FDA has recently approved new treatments for two significant health challenges: cardiovascular risk reduction in type 2 diabetes and lupus nephritis. Learn about the potential benefits of these advancements and what they mean for patient care.
3 min read